Sang Ho Oh
Department of Dermatology
Pigmentation, melasma, lentigo, bleaching agent, melanogenesis
Current development stage
General list: TRL3 Technology validated in lab
KR patent application
PCT Patent application
This study’s researchers discovered that one of purinergic receptors plays an important role in pigmentation. Among several kinds of purinergic receptors, they found P2X7R can mediate pigmentation in melanocytes by ultraviolet-induced ATP production from keratinocytes. Therefore, blockade of P2X7 receptor can be used to treat various pigmentation disorders through regulating ATP-mediated melanogenesis. Their results showed that the use of purinergic receptor agonists increased melanin synthesis while the use of purinergic receptor antagonists inhibited melanin synthesis.
These initial results show that there are compositions that can be used in the prevention or treatment of pigmentation disorders, such as those that result from hypopigmentation and hyperpigmentation. More specifically, these findings are focused on compositions that include purinergic receptor agonists and antagonists for the prevention and treatment of pigmentation disorders caused by hypopigmentation and hyperpigmentation, respectively.